Gut Microbiota Changes in Children Receiving Exclusive Enteral Nutrition With Compleat® Paediatric

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-16
SponsorEstablishment for Children and Adolescents in the Nantes Region

About this trial

This observational, prospective, single-center study aims to evaluate changes in the fecal microbiota of pediatric patients receiving exclusive enteral nutrition following the introduction of Compleat® Paediatric Nature Mix, an enteral formula made from food-derived ingredients. Secondary objectives include the assessment of digestive tolerance, bowel habits, sleep quality, enteral feeding rate, and related medication use over a six-month follow-up period.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Children aged 1 to 16 years

Exclusive enteral nutrition

Followed as part of routine care at the participating pediatric center

Legal guardians and caregivers able to understand French

Disqualifiers

Oral feeding or non-exclusive enteral nutrition

Use of oral nutritional supplements

Requirement for hypercaloric (>1.2 kcal/mL) or hypocaloric (<1 kcal/mL) enteral formulas

Acute clinical decompensation within one month prior to inclusion

Trial population

Children receiving exclusive enteral nutrition via gastrostomy and followed in a pediatric healthcare center.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Change in fecal microbiota composition between baseline (M0) and 2 months (M2), assessed by shotgun metagenomic analysis, with a focus on the relative abundance of Bifidobacterium.

Time frame
Baseline (M0) to Month 2 (M2)

Secondary outcomes

1

Change in bowel habits assessed using the Bristol Stool Scale

Bowel habits will be assessed using the Bristol Stool Form Scale, a 7-point scale ranging fromType 1 (hard lumps, severe constipation) to Type 7 (watery stool, severe diarrhea).

Time frame
Baseline, Month 1, Month 2, Month 3, and Month 6
2

Change in digestive tolerance assessed by the presence of bloating, abdominal distension, flatulence, nausea, regurgitation, and vomiting

Digestive tolerance will be assessed by the presence or absence and frequency of gastrointestinal symptoms, including bloating, abdominal distension, flatulence, nausea, regurgitation, and vomiting, recorded daily by caregivers in a clinical diary and analysed by symptomes decrease, stabilization or increase relative to the baseline state.

Time frame
Baseline, Month 1, Month 2, Month 3, and Month 6
3

Change in sleep quality assessed by nocturnal awakenings related to digestive symptoms

Sleep quality will be assessed by the incidence of nocturnal awakenings per night attributable to digestive symptoms, as reported daily by caregivers in a dedicated clinical diary.

Time frame
Baseline, Month 1, Month 2, Month 3, and Month 6
4

Change in enteral feeding rate (mL/hour)

Time frame
Baseline, Month 1, Month 2, Month 3, and Month 6

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.